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Non-small-cell lung cancers (NSCLCs) are largely classified into lung adenocarcinoma
(LUAD) and lung squamous cell carcinoma (LUSC), which have different therapeutic
options according to its molecular profiles and immune checkpoint expression,
especially PD-L1, which is a suppressive factor in the tumor microenvironment. The
tumor microenvironment can be altered by the genomic mutations on specific innate
immune genes as well as tumor suppressor genes, so it is essential to comprehend the
association between tumor microenvironment and tumor suppressor genes to discover
the promising immunotherapeutic strategy to overcome the resistance of immune check
point blockade. In this study, we aimed to analyze how the somatic mutations in tumor
suppressor genes affect the tumor immune microenvironment through a comprehensive
analysis of mutational profiling on the representative tumor suppressor genes (TP53,
CDKN2A, PTEN, RB1, BRCA1, BRCA2) and immune gene expression in The Cancer
Genome Atlas (TCGA) 155 lung squamous cell carcinoma (LUSC) and 196 lung
adenocarcinoma (LUAD) samples. Several microenvironmental factors, such as the
infiltrating immune and stromal cells, were suppressed by the mutated tumor suppressor
genes in LUSC, unlike in the LUAD samples. In particular, infiltrating immune cells such
as macrophage, neutrophil, and dendritic cells were significantly reduced in tumors with
mutated tumor suppressor genes’ group. In addition, the gene expressions for
interleukin production and lymphocyte differentiation and PGC, C7, HGF, PLA2G2A,
IL1RL1, CCR2, ALOX15B, CXCL11, FCN3 were significantly down-regulated, which
were key immune genes for the cross-talk between LUSC microenvironment and tumor
suppressors. Therefore, we generated evidence that TSG mutations in LUSC have anorg February 2021 | Volume 12 | Article 5986711
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Frontiers in Immunology | www.frontiersin.impact on tumor immune microenvironment, which suggests that TSG non-mutated
patients will have the more inflamed tumors and are more likely to respond to immune
checkpoint blockade therapy.Keywords: tumor suppressor gene, tumor microenvironment, The Cancer Genome Atlas, lung squamous cell
carcinoma, lung adenocarcinomaINTRODUCTION
Lung cancer is one of the most common cancers and the cause of
more than 25% of all cancer related deaths in men and women
around the world (1, 2). Non-small-cell lung cancers (NSCLCs)
consist of approximately 80% of lung cancers, which is classified
into lung adenocarcinoma (LUAD) and lung squamous cell
carcinoma (LUSC), and they have distinct molecular profiles
and therapeutic options according to the genotypes (3).
Especially, epidermal growth factor mutation (EGFR) tyrosine
kinase inhibitor, which is widely used for the targeted therapy
option and combination therapy with chemotherapy, has
emerged as a promising treatment in LUAD patients, whereas
LUSC has no targetable treatments for predisposed specific
genetic alterations owing to the largely unknown underlying
molecular mechanisms of LUSC pathogenesis (4–7).
The progression of cancer can be altered by the activity of
specific innate immune cells, which have a significant association
with the presence of tumor suppressors (8). The tumor-associated
macrophages (TAMs) and regulatory B cells have proven to have a
strong association with cancer progression and metastasis, and the
mutations in the tumor suppressor genes could regulate the function
of immune cells, particularly macrophage in preinvasive lesions (9–
11). Additionally, the macrophages, which were differentiated from
immature monocytes by cytokine, could enhance tumor suppressor
activity via NF-kB pathways (12). The tumor mutation burden
(TMB) and neoantigen burden are closely correlated with immune
response including cytolytic activity and immune checkpoints (13,
14). Moreover, recent studies suggest that immunogenic gene
expression is correlated with the response to therapy (15, 16).
The genomic alterations on tumor suppressor genes as well as
mutational burden considering the immune gene expression profiles
could provide the potential consequence of genomic alterations in
TSG on the tumor microenvironment (TME) and immune
checkpoints (17–19). Understanding the link between TME and
tumor suppressors is indispensable to find the immune interaction
between infiltrating immune and stromal cells and explore strategies
to optimize immune checkpoint blockade therapy in NSCLC.
Therefore, we focused on the role of tumor suppressors on the
immunity in TME to understand the fundamental mechanism of




We used whole exome and transcriptome data of TCGA 155
LUSC and 196 LUAD samples, respectively. The 101 Korean
LUSC cohort data which was previously published (20), was usedorg 2for the validation of the study. IRB review for use of the TCGA
patients data was exempted under TCGA policies which were in
accordance with Common Rule. Also, the 101 Korean LUSC
cohort was previously approved by the Institutional Review
Board of Seoul National University Hospital
The data preprocessing was performed by the previously
reported pipeline (20–22). The number of raw reads (HTSeq
count for Ensembl annotated gene) was transformed to variance
transformed data (R package ‘DESeq2’) for transcriptomic
sequencing analysis. The HTseq count values were converted
to Fragments Per Kilobase Million (FPKM) by R package
‘edgeR’. Also, the annotated VCF mutation files through the
Genomic Data Commons Data Portal (GDC Data Portal) were
assessed and downloaded for genomic analysis.
Classification of TSG Subtype and
Mutational Profiling
The subtypes considering tumor suppressor genes (TSGs) were
classified based on the presence and number of the non-
synonymous somatic mutations (missense, nonsense, frame
shift insertion, frame shift deletion, In-frame insertion, In-
frame deletion, and splice site mutation) in several key TSGs
(TP53, CDKN2A, PTEN, RB1, BRCA1, BRCA2), which were
previously reported as the representative TSGs (23).
Considering the presence of mutated TSGs, we defined TSG
non-mutated group as patients having no mutated TSGs, and
TSG mutated group as patients having equal to or greater than
one mutated TSGs. In addition, four subgroups were further
defined as non-TSG group (no mutated TSGs), TSG-1 (one TSG
mutation), TSG-2 (two TSG mutations), and TSG-3 (equal to or
greater than three TSG mutations) by considering the number of
the mutations on TSGs.
The mutation profiling on representative TSGs was
categorized and visualized with the mutation types and
frequency. The number of non-synonymous somatic mutations
for each patient was computed and compared between defined
subgroups across 155 TCGA LUSC samples.
Analysis of Differentially Expressed Genes
The up- or down-regulated differentially expressed genes (DEGs)
of TSG mutated group compared to TSG non-mutated group
and the adjusted p value were estimated by previously reported
method and significance criteria (adjusted P < 0.05, |Log2 (fold
change)| ≥ 1, and base mean ≥ 100)(R package ‘DESeq’) (21).
The gene enrichment analysis was performed by using the
computed DEGs in the TSG loss subtype via Gene Ontology
(GO) gene sets in the Molecular Signatures Database (MSigDB)
(GSEA web version).February 2021 | Volume 12 | Article 598671
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Immune Activity
Several immune factors such as the infiltrating immune cells
(B cells, CD4+ T cells, CD8+ T cells, neutrophil, macrophages,
and dendritic cells) and immune activity (stromal, immune,
cytolytic score, and tumor purity) were predicted by Tumor
IMune Estimation Resource (TIMER) and Estimation of STromal
and Immune cells in MAlignant Tumors using Expression data
(ESTIMATE) algorithm (24, 25). The computed values for immune
factors were statistically analyzed between subtypes considering the
distribution and number of samples in each group.
Calculation of Gene Expression Level of
Immune Genes
To represent the gene expression value, the variance stabilized
transformations (VST) normalized expression level were
converted from raw read counts (HTseq) by R package
‘DESeq2’, and the VST normalized expression of the selected
immune genes in TSG subtypes was box-plotted with the
corresponding Mann–Whitney U or unpaired Student t-test
depending on the sample distribution with Shapiro–Wilk
normality test (R package ‘ggplot2’) (26).
Characterization of Tumor
Microenvironment and Clinical Association
in TSG Loss Group
The clinical features such as TSG subtypes, gender, race, age, stage,
smoking status, site of resection, location in lung parenchyma, new
tumor event after initial treatment, person neoplasm cancer status,
pT, pN, pM, dimension of sample/specimen (longest, shortest, and
intermediate) were additionally summarized (Supplementary
Table 1). The association of TSG subtypes with the immune
checkpoint genes, clinical outcome, and parameters was analyzed
and visualized with the statistical analysis and R package ‘ggplot2’.
The expression (FPKM) of signature immune genes was adjusted to
median-centered and log2 transformed by R package ‘edge R’ and
Cluster 3.0.
Using the 144 TCGA LUSC samples who were provided with all
clinical information, overall survival rate and hazardous ratio inTSG
subtypes were computed by Kaplan–Meier estimates and a log-rank
test (R packages ‘survival’ and ‘surviminer’) from the obtained
TCGA clinical file (TMN stage, survival, age, sex, smoking status,
location in lung parenchyma, dimension of sample/specimen, new
tumor event after initial treatment), mutation load, and identified
immune genes such as KLK5, PGC, C7, HGF, PLA2G2A, IL1RL1,
CCR2, ALOX15B, CXCL11, and FCN3. Univariate andmultivariable
Cox regression models for overall survival were estimated by using
the R package ‘surviminer’ in LUSC patients.RESULTS
Identification of TSG Subtypes in TCGA
LUSC
In this study, the distribution of somatic nonsynonymous
mutations and the classification of TSG subtypes according toFrontiers in Immunology | www.frontiersin.org 3the number of mutations in TSG were described across 155
TCGA LUSC samples, and the somatic mutations located on
tumor suppressor genes were categorized with its mutational
types and frequency (Figure 1).
The TSG subtypes were defined by using the presence of the
mutations in the six different tumor suppressor genes such as
TP53, CDKN2A, PTEN, RB1, BRCA1, and BRCA2, which were
previously reported as the representative TSGs (23). Two
different subgroup classifications were applied to the LUSC
samples according to the presence and the number of
mutated TSGs.
Among the mutations in TSGs, the mutations encoding TP53
had the highest mutation frequency (78%), followed by CDKN2A
(15%), PTEN (8%), BRCA1 (6%), BRCA2 (6%) in the order of
frequency. Each TSGmutated and TSG non-mutated groups had
different patterns in four indicators for the immune response
[stromal score, immune score, tumor purity, and cytolytic
activity score (CYT score)], which CYT score represented the
degree of cell destruction by immune cells (27).
In order to identify the impact of TMB on the tumor
microenvironment, the correlation between immune and
stromal scores along with the TMB values was plotted according
to the number of mutated TSGs, and each immunogenic and
microenvironmental factor was compared in each four TSG
subtypes (Figures 1B, C). The tumor microenvironment
factors as represented by immune and stromal score, tumor
purity as well as mutation burdens were statistically different
between subtypes. However, there was no significant difference
in correlations between stromal and immune scores among the
four TSG subgroups (non-TSG: Pearson’s r = 0.78; TSG-1
Pearson’s r = 0.69; TSG-2: Pearson’s r = 0.68; TSG-3:
Pearson’s r = 0.7).
In the case of the TSG non-mutated and TSG mutated
subtypes according to the presence of mutated TGS, the TSG
mutated subgroup, which had equal to or greater than one
mutation in TSGs (n = 128), had lower stromal and immune
score than the TSG non-mutated subgroup (n = 27) which also
had higher tumor purity. Also, the overall infiltrating immune
cells [CD8+ T cells, CD4+ T cells, macrophage, dendritic cells
(DCs), and B cells, neutrophils] were more abundant in the TSG
non-mutated subgroup. In addition, the correlation between the
number of mutations in the TSG and the immune score was
investigated, and there was a negative association between them
(Spearman’s correlation r = −0.18, P < 0.05) (Supplementary
Figure 1).
The Association Between Tumor
Microenvironment and Immune Response
The different patterns of immune response in LUAD and LUSC
according to the presence of TSG mutation were identified, and
all factors representing immune response (stromal and immune
score, ESTIMATE score, tumor purity, CYT score, B cells, CD4+
T cells, CD8+ T cells, neutrophils, macrophages, and dendritic
cells) had no significant difference between TSG mutated and
TSG non-mutated groups in LUAD whereas the majority of
immune factors such as stromal and immune score, and
ESTIMATE score as well as infiltrating immune cellsFebruary 2021 | Volume 12 | Article 598671
Kim et al. Tumor Suppressor Genes and Immunity(macrophage, dendritic cells, and neutrophils) were significantly
lower in the TSG mutated group in LUSC (Supplementary
Figure 2).
In order to analyze the impact of TSG mutations on the TME
of LUSC, the association between infiltrating immune cells and
TME factors was investigated in each TSG subtype. TheFrontiers in Immunology | www.frontiersin.org 4correlation coefficient (r) between stromal and immune scores
was 0.78 in the TSG non-mutated group and 0.69 in the TSG
mutated group, and the tumor purity was lower as the stromal
and immune scores were increasing in both groups (Figure 2A),
and this revealed that the stromal scores of the TSG non-mutated
group were more positively associated with the immune scores.A
B C
FIGURE 1 | Identification of TSG subtypes in TCGA LUSC (n = 155). (A) The distribution of somatic nonsynonymous mutations (missense, nonsense, frame shift
insertion, frame shift deletion, In-frame insertion, In-frame deletion, and splice site mutation) and TSG subtypes according to the number of mutations in TSGs were
described across 155 TCGA LUSC samples, and the mutations on tumor suppressor genes were categorized with the mutation types and frequency. The four
different indicators for the immune response (stromal and immune score, tumor purity, and cytolytic score) and infiltrating immune cells (B cells, CD4+ T cells, CD8+ T
cells, neutrophil, macrophages, and dendritic cells) across the samples were displayed in each column. (B) The correlation between immune score and stromal score
along with the mutation burden was plotted in each of the four TSG subtypes with Pearson’s correlation coefficient. (C) The immune factors (immune and stromal
scores, tumor purity, mutation load, and cytolytic score) were box-plotted in four TSG subtypes. Each p-value was indicated by each of the subtypes (Kruskal–Wallis
or one-way ANOVA test).February 2021 | Volume 12 | Article 598671
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score, immune score, estimate score, and tumor purity) were
significantly lower in the TSG mutated group than in the TSG
non-mutated group (Figure 2B). Also, the infiltrating immune
cells such as neutrophils, macrophage, dendritic cells were
significantly increased in the TSG non-mutated group, and
these results accorded closely with the result of previous LUSC
cohorts (Supplementary Figure 3).
Gene Enrichment Analysis in TSG
Subtypes
The top 25 Gene Ontology (GO) gene sets in either down- and
up-regulated gene sets were investigated in the TSG mutatedFrontiers in Immunology | www.frontiersin.org 5group compared to the TSG non-mutated group based on the
rank of enrichment –log10(q value) of the pathway and the
matched significance criteria (P-value < 0.05 and FDR q value
< 0.1) (Figure 3A). Through the enrichment analysis, the
immune related gene sets such as regulation of humoral
immune response, regulation of inflammatory response,
regulation of chemokine secretion, and T cell migration were
significantly down-regulated whereas the tissue development,
neurogenesis, and neuron part gene sets were significantly up-
regulated in the TSG mutated group.
When we conducted the network visualization on gene
enrichment analysis, the gene sets for interleukin production
and leukocyte and lymphocyte differentiation were down-A
B
FIGURE 2 | The immune landscape of the microenvironment in TSG subtypes. (A) Scatterplots between stromal and immune scores with tumor purity gradient
were shown, and its correlation coefficient was indicated by each of the subtypes. The color grading corresponds to the tumor purity, indexed as shown on the color
bar at the bottom right of the panel. The median scores for stromal and immune scores were indicated by dashed lines under the horizontal (x) and vertical (y) axis.
(B) Several indicators for immune response and abundance of infiltrating B cells, CD4+ T cells, CD8+ T cells, neutrophil, macrophages, and dendritic cells in two
subtypes were estimated, and each p-value was indicated by each of the subtypes (Mann–Whitney U test and unpaired t-test). Box represents the median (thick line)
and the quartiles (line).February 2021 | Volume 12 | Article 598671
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biosynthetic process (P ≤ 0.05, FDR q value ≤ 0.01, and similarity
≤ 0.5) (Figure 3B). Next, we visualized each network of down-
regulated GO gene sets in TP53 and CDKN2Amutated group via
gene enrichment analysis. Similarly, the interleukin production,
leukocyte and lymphocyte differentiation, and mediated
immunity were significantly down-regulated in both TP53 and
CDKN2A-mutated groups (Supplementary Figure 4).
Impacts of TSG Loss on TME and Immune
Response in LUSC
The down-regulated immune genes in the TSG mutated group
were classified by each enriched GO immune gene sets andFrontiers in Immunology | www.frontiersin.org 6indicated with the p and q values (Figure 4A). Statistically,
KLK5, PGC, C7, HGF, PLA2G2A, IL1RL1, CCR2, ALOX15B,
CXCL11, and FCN3 were selected for the immune genes which
could affect the TSG activity, and those immune gene expressions
except for KLK5 and CXCL11 were significantly down-regulated
in the TSG mutated group compared to the TSG non-mutated
group (Figure 4B and Supplementary Figure 5). Among the
emerging immune checkpoint receptors and their respective
ligands, the expression of immune checkpoints such as VISTA
and CD28 and ligands on APCs such HVEM were significantly
up-regulated in the TSG mutated group, whereas other immune
checkpoint molecules such as PD-1 and PD-L1 were not
affected (28).A
B
FIGURE 3 | Gene enrichment analysis in TSG subtypes. (A) Top 25 GO gene sets in either down- and up-regulated GO gene sets were determined based on the
rank of enrichment –log10(q value) of the pathway and the matched significance criteria (P-value < 0.05 and FDR q value < 0.1) (B) Network visualization based on
gene enrichment analysis. Blue nodes represent the down-regulated gene sets in TSG subtype. Genes in significant networks were annotated and grouped with
simplified GO terms. Networks meeting the cut-off conditions detailed at the bottom of the figure (right) were visualized with the Enrichment Map plugin for
Cytoscape (P ≤ 0.05, FDR q value ≤ 0.01, and similarity ≤ 0.5).February 2021 | Volume 12 | Article 598671
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Clinical Outcome and Parameters
Kaplan–Meier survival analysis for 144 TCGA LUSC patients
indicated that there was no significant difference in overall
survival between the TSG non-mutated and TSG mutated
subtypes as well as four TSG subtypes (Kaplan–Meier
estimates; P = 0.11 for two TSG subtypes; P = 0.23 for four
TSG subtypes, Supplementary Figure 6). In fact, subgroup
classification was not a significant factor in determining the
clinical association in LUSC samples. Also, the hazardous ratio
along with the TSG subtypes, gender, age, stage, smoking status,
TMB, pT, pN, pM, dimension of sample/specimen (longest,
shortest, and intermediate), location in lung parenchyma, and
selected immune gene expressions was analyzed, and several
parameters such as PLA2G2A, FCN3, and new tumor event after
initial treatment in these clinical factors had some prognostic
value with univariate analysis (PLA2G2A: HR = 1.6, P = 0.046,
FCN3: HR = 1.8, P = 0.024, and new tumor event after initialFrontiers in Immunology | www.frontiersin.org 7treatment: HR = 1.8, p = 0.034, Table 1). Also, it was confirmed
that PLA2G2A and new tumor event after initial treatment were
statistically significant prognostic value with multivariable
analysis (PLA2G2A: HR = 1.8, p = 0.04 and new tumor event
after initial treatment: HR = 2.1, p = 0.01).DISCUSSION
The predictive and prognostic biomarkers for immune
checkpoints inhibitors (ICIs) have been developed by
estimating the PD-L1 expression level as well as the mutational
burden in the TME, but these were not sufficient to predict
response to the efficacy of immune checkpoint inhibitors, and it
has not considered the relative contribution of each immune cells
in the anti-tumor response (29–31). The cancer cells have
heterogeneous PD-L1 expression, and the small biopsies and
microarray could not detect the entire PD-L1 expression, whichA
B
FIGURE 4 | Impacts of mutated TSGs on immune response in LUSC. (A) The down-regulated immune genes in TSG subtype were classified by each enriched GO
immune gene sets and indicated with the p and q values. (B) The expression of the selected immune genes was depicted in the heatmap with the computed p-value
between TSG subtypes. The expression of immune checkpoint genes was analyzed and indicated with the p-value between TSG subtypes. All p-values were
computed by Mann–Whitney U test or unpaired t-test based on the sample distribution.February 2021 | Volume 12 | Article 598671
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resected tissue samples (32). Also, previous studies demonstrated
that the tumor suppressor inactivation enhanced inflammation
and altered TME (33).
In our study, the genomic and transcriptomic analyses were
useful in determining the impact of TSG loss on the TME and
immunity in LUSC.
The correlation between immune and stromal scores along
with the TMB values among four TSG subgroups indicated that
the stromal and immune cells were strongly correlated with the
mutational burden regardless of subtype, which was consistent
with previous results that the tumor cells with high TMB and the
formation of neoantigens had a decisive effect on the defective
immune system and TME including tumor immunogenicity
(22, 34).
Also, the negative association between the number of
mutations in TSG and the immune score confirmed that the
dysfunction in tumor suppressor genes such as p53 could have
an impact on stromal and immune cells in the TME, which may
accelerate tumor immune evasion, as described previously (35).
The TME of LUSC considering mutational profiling was more
useful in classifying TSG mutation mediated immune-deficient
subtype and establishing personalized immunotherapy treatment
options in LUSC patients (36, 37).Frontiers in Immunology | www.frontiersin.org 8The abundant infiltrating immune cells such as neutrophils,
macrophage, dendritic cells in the TSG non-mutated group
demonstrated that the abundance of infiltrating immune cells
was decreased by inactivation of tumor suppressor genes,
which could lead to result in the malignant transformation in
cancer cell (38). The infiltrating neutrophils in inflammatory
environments could attract the macrophages and dendritic cells
for enhancing tumor cell invasion and metastasis (39).
The interleukin production and lymphocyte differentiation
were significantly down-regulated in the TSG mutated LUSC
group. This suggests that several TSGs such as RB1, TP53, and
CDKN2A in LUSC, which are involved in various cellular
processes, including signaling pathways and DNA damage
repairing system, could have disturbed the interleukin-5
pathway, PD-1 signaling, cytotoxic T lymphocyte pathway (40).
Previously, it was confirmed that the overexpression of
interleukin 12 (IL12) induced the tumor-suppressive effect by
mediating antitumor activity, and mutated tumor suppressor genes
such as TP53 potentially regulated the immune cell infiltration
through its interaction with NF-kB and prevented activation of
cytotoxic T cells, NK cells, and macrophages (38, 41, 42).
In addition, the newly identified PGC, C7, HGF, PLA2G2A,
IL1RL1, CCR2, ALOX15B, CXCL11, and FCN3 genes, which were
down-regulated in the TSG mutated group, were key immuneTABLE 1 | Cox proportional hazards model analysis of overall survival in LUSC patients.
Overall survival (n = 144)
Variables Univariate analysis Multivariate analysis
HR 95% CI for HR P -value HR 95% CI for HR P -value
Age (≥60/<60) 1.1 (0.57–2.1) 0.81
Sex (male/female) 1.4 (0.80–2.5) 0.23
Smoking (smoker/non-smoker) 0.3 (0.082–1.4)) 0.20
pStage (II, III or IV/I) 1.0 (1.0-1.0) 0.58
pN (I, II, III or X/0) 1.0 (0.61–1.7) 0.92
pM (I or X/0) 1.2 (0.37–3.8) 0.79
pT (II, III or IV/I) 1.2 (0.71–2.2) 0.50










New tumor event after initial treatment (YES/NO) 1.8 (1.0–3.0) 0.034* 2.1 (1.2–3.6) 0.01**
Mutation load (high/low) 0.77 (0.48–1.2) 0.28
Group (TSG mutated group/TSG non-mutated group) 0.64 (0.37–1.1) 0.11
KLK5 (high/low) 1.0 (0.63–1.7) 0.92
PGC (high/low) 1.2 (0.72–1.9) 0.55
C7(high/low) 1.2 (0.75–2) 0.43
HGF(high/low) 1.0 (0.65–1.7) 0.84
PLA2G2A (high/low) 1.6 (1.0–2.7) 0.046* 1.8 (1.0–3.2) 0.04*
IL1RL1 (high/low) 0.75 (0.46–1.2) 0.23
CCR2(high/low) 0.77 (0.48–1.2) 0.29
ALOX15B (high/low) 1.2 (0.73–1.9) 0.50
CXCL11 (high/low) 0.84 (0.52–.14) 0.49
FCN3(high/low) 1.8 (1.1–2.9) 0.024* 1.5 (1.9–2.7) 0.12February 2021 | Volume 12 | ArticlHR, hazard ratio; CI, confidence interval.
*p < 0.05; **p < 0.01.e 598671
Kim et al. Tumor Suppressor Genes and Immunitygenes which might be involved in the crosstalk between cancer
microenvironment and tumor suppressors. These detected
immune response genes could be involved in regulating the
immune cell proliferation upon TSG inactivation in cancer
cells (18, 35, 40). Among the significantly up-regulated
immune checkpoint expression in the TSG mutated group,
VISTA, which is previously known as a PD-1 homolog and
shares a sequence homology both to CD28 and B7 families, could
be an immunotherapeutic target in the TSG non-mutated group
by regulating the T cell function (43). Further validation of the
function of key immune genes is needed to understand the
impact on the TME of LUSC.
Unexpectedly, the number of mutations in TSGs had weak
association with the survival, stage, and several clinical
parameters similar to previous study (44). However, immune
genes such as PLA2G2A and FCN3 had a statistically significant
association with overall survival, and the genomic alterations in
TSGs had an impact on the reduction in interleukin production,
leukocyte, and lymphocyte differentiation in TME, and
understanding the interaction between TSG and TME will be
useful to successfully treat LUSC patients.
Although we identified that TSG non-mutated patients may
have more inflamed tumors, our study is limited in that we have
not validated our findings in an independent patient cohort. We
presume that patients without TSG mutation are more likely to
respond to immune checkpoint blockade therapy, and this
hypothesis needs to be further validated in a separate analysis
involving LUSC patients who received anti-PD-1 or PD-L1
therapy. If these findings are proven, we may design a clinical
trial using immune checkpoint inhibitor and designate TSG
mutation status as a stratification factor or only include the
patients without TSGmutation to improve the efficacy outcomes.
In conclusion, we showed that TSG mutations in LUSC may
impact tumor immune microenvironment in that TSG non-
mutated patients will have more inflamed tumors and are more
likely to respond to immune checkpoint blockade therapy.Frontiers in Immunology | www.frontiersin.org 9Establishing the role of tumor suppressor genes on the tumor
immune environment could be useful to distinguish LUSC
patients who may respond or not respond to immune
checkpoint inhibitors if these findings are validated in
prospective LUSC patient cohorts.DATA AVAILABILITY STATEMENT
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